SUPERNUS PHARMACEUTICALS, INC. Debt Instrument, Convertible, Carrying Amount of Equity Component
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Debt Instrument, Convertible, Carrying Amount of Equity Component of $22.34 million as of 2013-12-31, per its 10-K/A filed 2017-01-20.
Discontinued › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent · last filed 2017-01-20
- 2013-12-31: Debt Instrument, Convertible, Carrying Amount of Equity Component $22.34M.
- 2013-09-30: Debt Instrument, Convertible, Carrying Amount of Equity Component $22.34M.
- 2013-06-30: Debt Instrument, Convertible, Carrying Amount of Equity Component $22.34M.
| Period end | Debt Instrument, Convertible, Carrying Amount of Equity Component |
|---|---|
| 2013-12-31 | $22.34M 10-K/A · filed 2017-01-20 |
| 2013-09-30 | $22.34M 10-Q · filed 2014-11-12 |
| 2013-06-30 | $22.34M 10-Q · filed 2013-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |